Supporting these findings, NF-κB1 sequencing informs liver function assessment [29], NFE2L2 activators counter hepatic lipotoxicity [30], and SERPINE1 serves as a biomarker in fatty liver disease and renal cancer progression [31,32]. Here, NFKB1 is linked to renal carcinoma.